Ionis licenses donidalorsen European rights to Otsuka; $65M upfront, tiered royalties

IONIS PHARMACEUTICALS INC

Otsuka receives exclusive European commercialization rights to donidalorsen (HAE prophylactic).
Ionis gets $65M upfront plus undisclosed regulatory/sales milestones.
Ionis eligible for tiered royalties of 20-30% on European net sales.
Ionis retains U.S. commercialization rights; plans to launch independently if approved.
Phase 3 donidalorsen data expected H1 2024; Phase 2 OLE showed 96% attack rate reduction.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

IONIS PHARMACEUTICALS INC entered into a license with Otsuka Pharmaceutical Co., Ltd. (effective 2023-12-18).

Action: entry
Agreement: license
Counterparty: Otsuka Pharmaceutical Co., Ltd.
Effective: 2023-12-18

Exact text from the filing

On December 18, 2023, Ionis Pharmaceuticals, Inc. issued a press release announcing it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (“ Otsuka ”) under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen, an investigational prophylactic treatment for hereditary angioedema (HAE).

View on SEC.gov

302 material agreements filed in the last 30 days. Browse all material agreements →

IONIS PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001140361-23-058152

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.